As of 1:33 PM on the 6th, SK is trading at 266,500 KRW, down 2.02% from the previous day. The trading volume is 1,096,629 shares, which is 91.32% of the previous day's volume. SK is known as the holding company of the SK Group.

On July 3rd, Choi Gwan-soon, a researcher at SK Securities, stated, "The successful IPO of SK Biopharm. Based on the closing price on the first day of listing, the value of SK's stake in SK Biopharm amounts to 7.4593 trillion KRW. Due to the shortage of circulating shares of SK Biopharm, if the stock price rises further, the value of SK's holdings will increase, easing valuation pressure. After SK Biopharm, the value of SK's unlisted subsidiaries such as SK Siltron and SK Pharmteco will also be re-emphasized." He set SK's target price at 390,000 KRW.

Over the past five days, individual investors have net purchased 269,745 shares of SK, while foreigners and institutions have net sold 400,894 shares and net purchased 110,011 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.



This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing